Efficacy and Safety of Dupilumab in Adolescent Patients with Moderate-to-Severe Atopic Dermatitis
April 2019
in “
Journal of Investigative Dermatology
”
Studysummary This study examined the safety and efficacy of dupilumab in adolescents with moderate-to-severe atopic dermatitis, finding that it was well tolerated and significantly improved symptoms over 52 weeks, with its safety profile similar to that in adults.
Automatically generated from the study's abstract, not written by a person, and not a review of the full paper. Not medical advice or a treatment recommendation. Read the original study, and consult a qualified healthcare professional before changing treatment. Full disclaimer
Read the full study on jidonline.org →